SWAN is pleased to announce a follow-on investment in Sonnest.

Sonnest is transforming cardiac ultrasound. Their Electrast™ is the first electrically sensitive imaging agent for assessing and monitoring the perfusion, structure, and function of the heart, allowing low cost ultrasound procedures to provide information only previously available from much higher cost scans. Electrast™ is a contrast agent that activates with ultrasound and the heart’s local electric field if the heart tissue is perfused and viable.

SWAN previously invested in Sonnest in February and May 2021.